Roche announced that its subsidiary Blue Giant Acquisition Corp has accepted for payment all shares of Poseida Therapeutics validly tendered and not withdrawn at a price of $9.00 per share in cash, plus a contingent value right to receive up to $4.00 per share in cash. The tender offer expired on January 7, 2025, and was not extended. A total of approximately 64,991,586 shares of Poseida's common stock were validly tendered, representing around 66.11% of the total outstanding shares. Roche intends to complete the acquisition of Poseida through a merger, where all remaining shares will be converted into the same consideration per share as received for shares validly tendered. Following the merger, Poseida will become a wholly owned subsidiary of Roche and its shares will cease to be traded on the Nasdaq Global Select Market. Poseida Therapeutics is a clinical-stage biopharmaceutical company advancing cell therapies and genetic medicines, with a pipeline including investigational allogeneic CAR-T cell therapies and in vivo genetic medicines. Roche is the world's largest biotechnology company and a global leader in in-vitro diagnostics, pursuing scientific excellence to discover and develop medicines and diagnostics. The company is committed to sustainability and has been an integral part of its business for over 125 years. Roche is subject to significant risks and uncertainties, including the possibility that milestone payments related to the contingent value right may never be achieved. The completion of the merger is expected to occur later in the day, with Roche's management believing the acquisition will have a positive impact on the company's portfolio and capabilities.